D2-like dopamine receptor neurons express inhibitory dopamine receptors (DRD2, DRD3, DRD4) that mediate motor control, reward processing, and cognitive functions. These neurons are critically involved in Parkinson's disease (PD), Huntington's disease (HD), schizophrenia, and addiction. D2 receptor dysfunction is a hallmark of dopaminergic neurodegeneration[1].
| Property | Value |
|---|---|
| Category | Dopamine Receptor Neurons |
| Location | Striatum, VTA, PFC, Nucleus Accumbens |
| Receptor Type | D2 (DRD2), D3 (DRD3), D4 (DRD4) |
| Signaling | Gi-coupled, inhibitory |
| Neurotransmitter | GABA (striatal), Dopamine (modulatory) |
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:0000197 | sensory receptor cell |
D2-like receptors share common structural features[2]:
| Receptor | Brain Region | Cell Type Expression |
|---|---|---|
| DRD2 | Striatum | Indirect pathway MSNs, cholinergic interneurons |
| DRD3 | Limbic system | Ventral striatum, islands of Calleja |
| DRD4 | Cortex, hippocampus | Pyramidal neurons, interneurons |
D2-expressing neurons in the striatum form the indirect pathway[3]:
D2 neurons encode reward prediction and motivation[4]:
Prefrontal D2 receptors modulate working memory and attention[5]:
D2 receptor neurons are central to PD pathophysiology[6]:
Therapeutic implications:
D2-expressing neurons are particularly vulnerable in HD[7]:
Research findings:
D2 receptor dysfunction contributes to AD symptoms[9]:
D2 receptor hyperactivity is a key feature of schizophrenia[10]:
Single-cell RNA sequencing has characterized D2 neurons[11]:
Marker genes:
Disease-associated genes:
AAV-mediated D2 receptor delivery
CRISPR editing of D2 receptor variants
RNA targeting of D2 transcript
D1-Like Dopamine Receptor Neurons
Striatal Medium Spiny Neurons
Parkinson's Diseaseparkin)
Dopamine Signaling Pathway
Basal Ganglia Circuitry
The study of D2 Like Dopamine Receptor Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011;63(1):182-217. 2011. ↩︎
Missale C, Nash SR, Robinson SW. Dopamine receptors: from structure to function. Physiol Rev. 1998;78(1):189-225. 1998. ↩︎
[Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989;12(10):366-375](https://doi.org/10.1016/0166-2236(89). 1989. ↩︎
Schultz W. Predictive reward signal of dopamine neurons. J Neurophysiol. 1998;80(1):1-27. 1998. ↩︎
Goldman-Rakic PS. Working memory dysfunction in schizophrenia. J Neuropsychiatry Clin Neurosci. 1994;6(4):348-357. 1994. ↩︎
[Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015;386(9996):896-912](https://doi.org/10.1016/S0140-6736(14). 2015. ↩︎
[Glass M, Dragunow M, Faull RL. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia. Neuroscience. 2000;100(4):683-693](https://doi.org/10.1016/S0306-4522(00). 2000. ↩︎
Pavese N, Tai YF, Barker GJ. Striatal dopamine transporter binding correlates with clinical severity in Huntington disease. Neurology. 2021;97(9):e896-e905. 2021. ↩︎
Martorana A, Koch G. Is dopamine involved in Alzheimer's disease? Curr Alzheimer Res. 2014;11(10):944-959. 2014. ↩︎
Howes OD, Kambeitz J, Kim E. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry. 2012;69(8):776-786. 2012. ↩︎
Gokce O, Stanley GM, Treutlein B. Cellular taxonomy of the mouse striatum revealed by single-cell RNA-seq. Cell Rep. 2016;16(4):1126-1137. 2016. ↩︎